A 2026 BD opportunity scan of Etern Therapeutics, covering pipeline ownership, development stage, evidence package, IP risk, deal precedents, financial signals and outreach rationale using PatSnap MCP workflows.

A 2026 BD opportunity scan of CKD Pharmaceutical Corp., covering pipeline ownership, development stage, evidence package, IP risk, deal precedents, financial signals and outreach rationale using PatSnap MCP workflows.

A 2026 BD opportunity scan of Cosette Pharmaceuticals, Inc., covering pipeline ownership, development stage, evidence package, IP risk, deal precedents, financial signals and outreach rationale using PatSnap MCP workflows.

A 2026 BD opportunity scan of Bao Pharma, covering pipeline ownership, development stage, evidence package, IP risk, deal precedents, financial signals and outreach rationale using PatSnap MCP workflows.

A 2026 BD opportunity scan of Arrotex Pharmaceuticals, covering pipeline ownership, development stage, evidence package, IP risk, deal precedents, financial signals and outreach rationale using PatSnap MCP workflows.

A 2026 BD opportunity scan of EGIS Pharmaceuticals, covering pipeline ownership, development stage, evidence package, IP risk, deal precedents, financial signals and outreach rationale using PatSnap MCP workflows.

A 2026 BD opportunity scan of Amoytop Biotech, covering pipeline ownership, development stage, evidence package, IP risk, deal precedents, financial signals and outreach rationale using PatSnap MCP workflows.

A 2026 BD opportunity scan of EA Pharma Co., Ltd., covering pipeline ownership, development stage, evidence package, IP risk, deal precedents, financial signals and outreach rationale using PatSnap MCP workflows.

A 2026 BD opportunity scan of Abogen Biosciences, covering pipeline ownership, development stage, evidence package, IP risk, deal precedents, financial signals and outreach rationale using PatSnap MCP workflows.

A 2026 BD opportunity scan of Fuji Pharma Co. Ltd., covering pipeline ownership, development stage, evidence package, IP risk, deal precedents, financial signals and outreach rationale using PatSnap MCP workflows.

A 2026 BD opportunity scan of Chengdu Baiyu Pharmaceutical Co. Ltd., covering pipeline ownership, development stage, evidence package, IP risk, deal precedents, financial signals and outreach rationale using PatSnap MCP workflows.

Evaluate Hamman-Rich Syndrome with 2026 evidence on epidemiology, target biology, clinical competition, unmet need, deals and market attractiveness via Patsnap MCP..